Acute	acute	O	B_disease
renal	renal	O	B_disease
failure	failure	O	I_disease
in	in	O	O
patients	patients	O	O
with	with	O	O
AIDS	aids	O	S_disease
on	on	O	O
tenofovir	tenofovir	O	O
while	while	O	O
receiving	receiving	O	O
prolonged	prolonged	O	O
vancomycin	vancomycin	S_chemical	O
course	course	O	O
for	for	O	O
osteomyelitis	osteomyelitis	O	O
.	.	O	O

Renal	renal	O	B_disease
failure	failure	O	I_disease
developed	developed	O	O
after	after	O	O
a	a	O	O
prolonged	prolonged	O	O
course	course	O	O
of	of	O	O
vancomycin	vancomycin	S_chemical	O
therapy	therapy	O	O
in	in	O	O
2	2	O	O
patients	patients	O	O
who	who	O	O
were	were	O	O
receiving	receiving	O	O
tenofovir	tenofovir	O	O
disoproxil	disoproxil	O	O
fumarate	fumarate	O	O
as	as	O	O
part	part	O	O
of	of	O	O
an	an	O	O
antiretroviral	antiretroviral	O	O
regimen	regimen	O	O
.	.	O	O

Tenofovir	tenofovir	O	O
has	has	O	O
been	been	O	O
implicated	implicated	O	O
in	in	O	O
the	the	O	O
development	development	O	O
of	of	O	O
Fanconi	fanconi	O	B_disease
syndrome	syndrome	O	I_disease
and	and	O	O
renal	renal	O	B_disease
insufficiency	insufficiency	O	I_disease
because	because	O	O
of	of	O	O
its	its	O	O
effects	effects	O	O
on	on	O	O
the	the	O	O
proximal	proximal	O	O
renal	renal	O	O
tubule	tubule	O	O
.	.	O	O

Vancomycin	vancomycin	S_chemical	O
nephrotoxicity	nephrotoxicity	O	S_disease
is	is	O	O
infrequent	infrequent	O	O
but	but	O	O
may	may	O	O
result	result	O	O
from	from	O	O
coadministration	coadministration	O	O
with	with	O	O
a	a	O	O
nephrotoxic	nephrotoxic	O	S_disease
agent	agent	O	O
.	.	O	O

Clinicians	clinicians	O	O
should	should	O	O
be	be	O	O
aware	aware	O	O
that	that	O	O
tenofovir	tenofovir	O	O
may	may	O	O
raise	raise	O	O
the	the	O	O
risk	risk	O	O
of	of	O	O
renal	renal	O	B_disease
failure	failure	O	I_disease
during	during	O	O
prolonged	prolonged	O	O
administration	administration	O	O
of	of	O	O
vancomycin	vancomycin	S_chemical	O
.	.	O	O

